Education, Research & Positions
Anti-PD-1 therapy in unresectable desmoplastic melanoma: the phase 2 SWOG
Anti-PD-1 therapy in unresectable desmoplastic melanoma: the phase 2 SWOG S1512 trial Summary The SWOG S1512 phase 2 trial investigated pembrolizumab (anti-PD-1 therapy) in patients with unresectable desmoplastic melanoma (DM), a rare and aggressive subtype. The study Read More
